SEC Form 4 · accession 0001209191-17-040548
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J. Scott Garland
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 16, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonstatutory Stock Option (right to buy)F1 | $9.18 | Jun 15, 2017 | A | 17,000 | A | — | Jun 14, 2027 | Common Stock | 17,000 | 17,000 | D |
Explanation of responses
- F1This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date.